CN104650068B - 二氢嘧啶类化合物及其在药物中的应用 - Google Patents
二氢嘧啶类化合物及其在药物中的应用 Download PDFInfo
- Publication number
- CN104650068B CN104650068B CN201410657898.XA CN201410657898A CN104650068B CN 104650068 B CN104650068 B CN 104650068B CN 201410657898 A CN201410657898 A CN 201410657898A CN 104650068 B CN104650068 B CN 104650068B
- Authority
- CN
- China
- Prior art keywords
- compound
- alkyl
- independently
- methyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *C1Nc2ccccc2C=C1 Chemical compound *C1Nc2ccccc2C=C1 0.000 description 19
- CCPVCZYOGHGBBD-NMXLAWLUSA-N CC(C[C@@H](C1)N(CC(NC(c2ncc[s]2)=N[C@H]2c(c(Cl)c3)ccc3F)=C2C(OC)=O)CC1(F)F)C(O)=O Chemical compound CC(C[C@@H](C1)N(CC(NC(c2ncc[s]2)=N[C@H]2c(c(Cl)c3)ccc3F)=C2C(OC)=O)CC1(F)F)C(O)=O CCPVCZYOGHGBBD-NMXLAWLUSA-N 0.000 description 1
- OGUVUOIKRVWUDL-ZDUSSCGKSA-N CC(NC(c1ncc[s]1)=N[C@H]1c(c(Cl)c2)ccc2Cl)=C1C(OC)=O Chemical compound CC(NC(c1ncc[s]1)=N[C@H]1c(c(Cl)c2)ccc2Cl)=C1C(OC)=O OGUVUOIKRVWUDL-ZDUSSCGKSA-N 0.000 description 1
- CWKTUACHRCCTNM-WQVVZYPJSA-N CC1(C2=N[C@@H](c(c(Cl)c3)ccc3F)C(C(OC)=O)=C(CN(C3)[C@@H](CCCCC(O)=O)CC3(F)F)N2)SC=CN1 Chemical compound CC1(C2=N[C@@H](c(c(Cl)c3)ccc3F)C(C(OC)=O)=C(CN(C3)[C@@H](CCCCC(O)=O)CC3(F)F)N2)SC=CN1 CWKTUACHRCCTNM-WQVVZYPJSA-N 0.000 description 1
- FMXVSJPWIBXXKQ-XLDIYJRPSA-N CCOC(C1=C(CN(C2)C(CC(NC(C(C3CC3)=O)=O)=O)CC2(F)F)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN(C2)C(CC(NC(C(C3CC3)=O)=O)=O)CC2(F)F)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O FMXVSJPWIBXXKQ-XLDIYJRPSA-N 0.000 description 1
- LICCPCYNFDNCBM-JQHMPQBSSA-N CCOC(C1=C(CN(C2)[C@@H](CC(C)C(N=O)=O)CC2(F)F)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN(C2)[C@@H](CC(C)C(N=O)=O)CC2(F)F)NC(c2ncc[s]2)=N[C@H]1c(c(Br)c1)ccc1F)=O LICCPCYNFDNCBM-JQHMPQBSSA-N 0.000 description 1
- FAVFYVJJBLNTBK-HKUYNNGSSA-N CCOC(C1=C(CN(CCSC2)[C@@H]2C(NOC)=O)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1F)=O Chemical compound CCOC(C1=C(CN(CCSC2)[C@@H]2C(NOC)=O)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1F)=O FAVFYVJJBLNTBK-HKUYNNGSSA-N 0.000 description 1
- PYWSMGHXJUXUSK-VIFPVBQESA-N CCOC([C@H](CCC(C1)(F)F)N1C(OC(C)(C)C)=O)=O Chemical compound CCOC([C@H](CCC(C1)(F)F)N1C(OC(C)(C)C)=O)=O PYWSMGHXJUXUSK-VIFPVBQESA-N 0.000 description 1
- ONELXRQCJBCEOV-ZDUSSCGKSA-N COC(C1=C(CBr)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1F)=O Chemical compound COC(C1=C(CBr)NC(c2ncc[s]2)=N[C@H]1c(c(Cl)c1)ccc1F)=O ONELXRQCJBCEOV-ZDUSSCGKSA-N 0.000 description 1
- BHRBGLXLHBPROD-VLIAUNLRSA-N C[n]1c(C2=N[C@@H](c(c(Cl)c3)ccc3F)C(C(OC)=O)=C(CN(C3)[C@H](CCC(O)=O)CC3(F)F)N2)ncc1 Chemical compound C[n]1c(C2=N[C@@H](c(c(Cl)c3)ccc3F)C(C(OC)=O)=C(CN(C3)[C@H](CCC(O)=O)CC3(F)F)N2)ncc1 BHRBGLXLHBPROD-VLIAUNLRSA-N 0.000 description 1
- XMIAFAKRAAMSGX-UHFFFAOYSA-N Nc1cccc2ncccc12 Chemical compound Nc1cccc2ncccc12 XMIAFAKRAAMSGX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410657898.XA CN104650068B (zh) | 2013-11-19 | 2014-11-18 | 二氢嘧啶类化合物及其在药物中的应用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013105906836 | 2013-11-19 | ||
| CN201310590683 | 2013-11-19 | ||
| CN201410108925 | 2014-03-23 | ||
| CN2014101089258 | 2014-03-23 | ||
| CN201410657898.XA CN104650068B (zh) | 2013-11-19 | 2014-11-18 | 二氢嘧啶类化合物及其在药物中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104650068A CN104650068A (zh) | 2015-05-27 |
| CN104650068B true CN104650068B (zh) | 2018-08-10 |
Family
ID=53178948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410657898.XA Active CN104650068B (zh) | 2013-11-19 | 2014-11-18 | 二氢嘧啶类化合物及其在药物中的应用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9498479B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3071564B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6524081B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20160077050A (cg-RX-API-DMAC7.html) |
| CN (1) | CN104650068B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014352404B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2920415A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2016006564A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2678990C1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015074546A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102284938B1 (ko) | 2013-11-27 | 2021-08-02 | 선샤인 레이크 파르마 컴퍼니 리미티드 | 다이하이드로피리미딘 유도체 및 이의 중간산물의 제조 방법 |
| CN104945395B (zh) | 2014-03-28 | 2018-01-23 | 广东东阳光药业有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
| US10098889B2 (en) | 2015-02-07 | 2018-10-16 | Sunshine Lake Pharma Co., Ltd. | Complexes and salts of dihydropyrimidine derivatives and their application in pharmaceuticals |
| US20160286398A1 (en) * | 2015-03-23 | 2016-09-29 | Qualcomm Incorporated | Schedule selection and connection setup between devices participating in a nan data link |
| US10442788B2 (en) | 2015-04-01 | 2019-10-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| WO2016183266A1 (en) | 2015-05-13 | 2016-11-17 | Enanta Pharmaceuticals, Inc. | Ehpatitis b antiviral agents |
| US10179131B2 (en) | 2015-07-13 | 2019-01-15 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US10301255B2 (en) | 2015-07-22 | 2019-05-28 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| JP6668468B2 (ja) | 2015-11-03 | 2020-03-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｈｂｖキャプシドアセンブリ阻害剤とインターフェロンの併用療法 |
| WO2017136403A1 (en) | 2016-02-02 | 2017-08-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| WO2017136254A1 (en) * | 2016-02-04 | 2017-08-10 | Merck Sharp & Dohme Corp. | Methods of preparing hydroxylamine derivatives useful in the preparation of anti-infective agents |
| KR102398439B1 (ko) | 2016-03-07 | 2022-05-16 | 이난타 파마슈티칼스, 인코포레이티드 | B형 간염 항바이러스제 |
| CA3028228A1 (en) | 2016-06-10 | 2017-12-14 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| JP2019526562A (ja) | 2016-08-24 | 2019-09-19 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｈｂｖキャプシドアセンブリ阻害剤とヌクレオシ（チ）ド類似体の併用療法 |
| WO2018090862A1 (zh) * | 2016-11-18 | 2018-05-24 | 四川科伦博泰生物医药股份有限公司 | 二氢嘧啶类化合物及其制备方法和用途 |
| US11166954B2 (en) | 2016-11-18 | 2021-11-09 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Dihydropyrimidine compound and preparation method and use thereof |
| AU2018290511B2 (en) * | 2017-06-26 | 2022-01-27 | Sunshine Lake Pharma Co., Ltd. | Dihydropyrimidine compounds and uses thereof in medicine |
| AU2018291688B2 (en) | 2017-06-27 | 2022-02-03 | Janssen Pharmaceutica Nv | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections |
| SG11202001685TA (en) | 2017-08-28 | 2020-03-30 | Enanta Pharm Inc | Hepatitis b antiviral agents |
| MY194405A (en) * | 2017-10-18 | 2022-11-30 | Sunshine Lake Pharma Co Ltd | Dihydropyrimidine compounds and uses thereof in medicine |
| WO2019113173A1 (en) | 2017-12-06 | 2019-06-13 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| WO2019113175A1 (en) | 2017-12-06 | 2019-06-13 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| WO2019191166A1 (en) | 2018-03-29 | 2019-10-03 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| CN108329308B (zh) | 2018-05-16 | 2022-11-01 | 四川科伦博泰生物医药股份有限公司 | 一种二氢嘧啶类化合物的固体形式及其制备方法 |
| US11053235B2 (en) | 2018-08-09 | 2021-07-06 | Janssen Sciences Ireland Unlimited Company | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases |
| JP2022500466A (ja) | 2018-09-21 | 2022-01-04 | エナンタ ファーマシューティカルズ インコーポレイテッド | 抗ウイルス剤としての官能化複素環 |
| US20210395751A1 (en) | 2018-10-31 | 2021-12-23 | The University Of Sydney | Compositions and methods for treating viral infections |
| IL283190B2 (en) | 2018-11-21 | 2025-08-01 | Enanta Pharm Inc | Functionalized heterocycles as antiviral agents |
| WO2020247444A1 (en) | 2019-06-03 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| WO2020247575A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| WO2020247561A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| US11236108B2 (en) | 2019-09-17 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| WO2021188414A1 (en) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| CN113831359B (zh) * | 2020-06-24 | 2026-03-06 | 广东东阳光药业股份有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
| CN118955353A (zh) * | 2024-10-14 | 2024-11-15 | 南京恒远科技开发有限公司 | 一种(s)-4,4-二氟-1-甘氨酰吡咯烷-2-氰基的合成方法 |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001068641A1 (de) * | 2000-03-17 | 2001-09-20 | Bayer Aktiengesellschaft | 6-aminoalkyl-dihydroppyrimidine und ihre verwendung als arzneimittel gegen virale erkrankungen |
| EP1265889B1 (de) * | 2000-03-16 | 2004-06-16 | Bayer HealthCare AG | Arzneimittel gegen virale erkrankungen |
| CN101328168A (zh) * | 2007-06-18 | 2008-12-24 | 张中能 | 一种乙氧碳酰基-取代噻唑二氢嘧啶 |
| CN103626752A (zh) * | 2012-08-24 | 2014-03-12 | 广东东阳光药业有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
| WO2014037480A1 (en) * | 2012-09-10 | 2014-03-13 | F. Hoffmann-La Roche Ag | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| CN103664897A (zh) * | 2012-09-01 | 2014-03-26 | 广东东阳光药业有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
| CN103664899A (zh) * | 2012-09-11 | 2014-03-26 | 广东东阳光药业有限公司 | 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用 |
| CN103664925A (zh) * | 2012-09-07 | 2014-03-26 | 广东东阳光药业有限公司 | 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用 |
| CN104672222A (zh) * | 2013-11-27 | 2015-06-03 | 广东东阳光药业有限公司 | 二氢嘧啶衍生物的制备方法及其中间体 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61271278A (ja) | 1985-05-20 | 1986-12-01 | イ− ア−ル スクイブ アンド サンズ インコ−ポレ−テツド | ２−置換チオまたはオキソ−４−アリ−ルまたはヘテロシクロ−５−カルボキシ−１，４−ジヒドロピリミジン |
| GB8906168D0 (en) | 1989-03-17 | 1989-05-04 | Pfizer Ltd | Therapeutic agents |
| SE9702563D0 (sv) | 1997-07-02 | 1997-07-02 | Astra Ab | Compounds |
| SE9702564D0 (sv) | 1997-07-02 | 1997-07-02 | Astra Ab | New compounds |
| DE19817264A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Neue Dihydropyrimidine |
| DE19817262A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Neue 2-heterocyclisch substituierte Dihydropyrimidine |
| DE19817265A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Verwendung von Dihydropyrimidinen als Arzneimittel und neue Stoffe |
| WO2000058302A1 (de) | 1999-03-25 | 2000-10-05 | Bayer Aktiengesellschaft | Dihydropyrimidine und ihre verwendung zur behandlung von hepatitis b |
| DE10012549A1 (de) | 2000-03-15 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10012824A1 (de) | 2000-03-16 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| DE10013125A1 (de) | 2000-03-17 | 2001-09-20 | Bayer Ag | Arzneimittel gegen virale Erkrankungen |
| US7157461B2 (en) | 2003-07-23 | 2007-01-02 | Bristol-Myers Squibb Co. | Substituted dihydropyrimidine inhibitors of calcium channel function |
| CN101104617B (zh) | 2006-07-10 | 2010-06-23 | 北京摩力克科技有限公司 | 二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途 |
| CN101104604B (zh) | 2006-07-10 | 2011-03-02 | 北京摩力克科技有限公司 | 光学纯二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途 |
| CN101225084A (zh) | 2007-01-16 | 2008-07-23 | 北京摩力克科技有限公司 | 二氢嘧啶类化合物及其用于制备治疗和预防病毒性疾病的药物的用途 |
| CN101328170B (zh) | 2007-06-18 | 2011-09-14 | 张中能 | 一种氟苯基-取代噻唑二氢嘧啶 |
| AU2008265397C1 (en) | 2007-06-18 | 2013-08-29 | Sunshine Lake Pharma Co., Ltd. | Bromo-phenyl substituted thiazolyl dihydropyrimidines |
| WO2008154819A1 (fr) | 2007-06-18 | 2008-12-24 | Zhang, Zhongneng | Thiazolyl-dihydropyrimidines à substitution carbéthoxy |
| CN101744823B (zh) | 2008-12-17 | 2013-06-19 | 广东东阳光药业有限公司 | 一种二氢嘧啶类化合物的固体分散体及其药用制剂 |
| WO2010069147A1 (zh) | 2008-12-17 | 2010-06-24 | 张中能 | 二氢嘧啶类化合物、其组合物及其应用 |
| CN101575318B (zh) | 2009-06-25 | 2012-02-08 | 中国人民解放军军事医学科学院毒物药物研究所 | 二氢嘧啶类化合物及其用于制备治疗和/或预防病毒性疾病的药物的用途 |
| US9487534B2 (en) | 2011-08-02 | 2016-11-08 | Scripps Research Institute, A Not-For-Profit Public Benefit Corporation Of California | Modulators of virus assembly as antiviral agents |
| EP2800742B1 (en) | 2012-01-06 | 2016-04-06 | Janssen Sciences Ireland UC | 4,4-disubstituted-1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis b |
| US20130267517A1 (en) | 2012-03-31 | 2013-10-10 | Hoffmann-La Roche Inc. | Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| ES2575398T3 (es) * | 2012-03-31 | 2016-06-28 | F. Hoffmann-La Roche Ag | 4-Metil-dihidropirimidinas novedosas para el tratamiento y la profilaxis de la infección por el virus de la hepatitis B |
| HK1215030A1 (zh) | 2012-11-09 | 2016-08-12 | Indiana University Research And Technology Corporation | 用於hbv組裝效應劑的替代用途 |
| SG11201507698QA (en) | 2013-03-20 | 2015-10-29 | Univ Indiana Res & Tech Corp | Fluorescent-hap: a diagnostic stain for hbv cores in cells |
| BR112015028873A2 (pt) | 2013-05-17 | 2017-07-25 | Hoffmann La Roche | heteroaril-diidro-pirimidinas interligados na posição 6, para o tratamento e profilaxia de infecção pelo vírus da hepatite b |
-
2014
- 2014-11-18 WO PCT/CN2014/091444 patent/WO2015074546A1/en not_active Ceased
- 2014-11-18 RU RU2016122908A patent/RU2678990C1/ru active
- 2014-11-18 AU AU2014352404A patent/AU2014352404B2/en active Active
- 2014-11-18 KR KR1020167008618A patent/KR20160077050A/ko not_active Withdrawn
- 2014-11-18 EP EP14863769.7A patent/EP3071564B1/en active Active
- 2014-11-18 CN CN201410657898.XA patent/CN104650068B/zh active Active
- 2014-11-18 US US15/022,562 patent/US9498479B2/en active Active
- 2014-11-18 JP JP2016530248A patent/JP6524081B2/ja active Active
- 2014-11-18 MX MX2016006564A patent/MX2016006564A/es unknown
- 2014-11-18 CA CA2920415A patent/CA2920415A1/en not_active Abandoned
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1265889B1 (de) * | 2000-03-16 | 2004-06-16 | Bayer HealthCare AG | Arzneimittel gegen virale erkrankungen |
| WO2001068641A1 (de) * | 2000-03-17 | 2001-09-20 | Bayer Aktiengesellschaft | 6-aminoalkyl-dihydroppyrimidine und ihre verwendung als arzneimittel gegen virale erkrankungen |
| CN101328168A (zh) * | 2007-06-18 | 2008-12-24 | 张中能 | 一种乙氧碳酰基-取代噻唑二氢嘧啶 |
| CN103626752A (zh) * | 2012-08-24 | 2014-03-12 | 广东东阳光药业有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
| CN103664897A (zh) * | 2012-09-01 | 2014-03-26 | 广东东阳光药业有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
| CN103664925A (zh) * | 2012-09-07 | 2014-03-26 | 广东东阳光药业有限公司 | 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用 |
| WO2014037480A1 (en) * | 2012-09-10 | 2014-03-13 | F. Hoffmann-La Roche Ag | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| CN103664899A (zh) * | 2012-09-11 | 2014-03-26 | 广东东阳光药业有限公司 | 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用 |
| CN104672222A (zh) * | 2013-11-27 | 2015-06-03 | 广东东阳光药业有限公司 | 二氢嘧啶衍生物的制备方法及其中间体 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104650068A (zh) | 2015-05-27 |
| JP2016537358A (ja) | 2016-12-01 |
| US20160206616A1 (en) | 2016-07-21 |
| HK1224286A1 (en) | 2017-08-18 |
| CA2920415A1 (en) | 2015-05-28 |
| RU2678990C1 (ru) | 2019-02-05 |
| EP3071564A1 (en) | 2016-09-28 |
| US9498479B2 (en) | 2016-11-22 |
| KR20160077050A (ko) | 2016-07-01 |
| MX2016006564A (es) | 2017-09-12 |
| AU2014352404A1 (en) | 2016-02-18 |
| EP3071564A4 (en) | 2017-04-26 |
| JP6524081B2 (ja) | 2019-06-05 |
| EP3071564B1 (en) | 2020-08-05 |
| WO2015074546A1 (en) | 2015-05-28 |
| RU2016122908A (ru) | 2017-12-25 |
| AU2014352404B2 (en) | 2018-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104650068B (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| CN104945395B (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| CN104926808B (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| CN103664897B (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| CN109678859B (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| CN103664925B (zh) | 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用 | |
| CN104650069A (zh) | 4-甲基二氢嘧啶类化合物及其在药物中的应用 | |
| CN103664899B (zh) | 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用 | |
| CN104650070B (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| EP3912975A1 (en) | Lysophosphatidic acid receptor antagonists and preparation method therefor | |
| EP4089080A1 (en) | RORyT INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | |
| CN109111451B (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| CN107108588A (zh) | 可用于治疗癌症的稠合双环(杂)芳香族化合物 | |
| WO2022143610A1 (zh) | 新型酰胺吡咯类化合物及其在药物中的应用 | |
| WO2023116748A1 (zh) | 取代的杂芳基化合物及其组合物和用途 | |
| CN116836167A (zh) | 咪唑并[1,2-a]吡嗪或吡唑并[1,5-a]嘧啶衍生物及其用途 | |
| WO2021197486A1 (zh) | 新型螺环类化合物及其在药物中的应用 | |
| EP4089079A1 (en) | Ror gamma t inhibitor, preparation method therefor and use thereof | |
| HK1224286B (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| HK40083400A (en) | RORγT INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | |
| HK40083401A (en) | Ror gamma t inhibitor, preparation method therefor and use thereof | |
| EP4671242A1 (en) | PYRIDOPYRIMIDINE DERIVATIVE AND ITS USES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Heteroaryl-substituted dihydropyrimidine compounds and application thereof in medicines Effective date of registration: 20200514 Granted publication date: 20180810 Pledgee: Zhongrong International Trust Co.,Ltd. Pledgor: SUNSHINE LAKE PHARMA Co.,Ltd. Registration number: Y2020990000464 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220915 Granted publication date: 20180810 Pledgee: Zhongrong International Trust Co.,Ltd. Pledgor: SUNSHINE LAKE PHARMA Co.,Ltd. Registration number: Y2020990000464 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| CP03 | Change of name, title or address |
Address after: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province Patentee after: Guangdong Dongyangguang Pharmaceutical Co.,Ltd. Address before: 523000 Songshan Lake Science and Technology Industrial Park, Dongguan, Guangdong (No. 1 Industrial North Road, Hubei Industrial Park, Songshan) Patentee before: SUNSHINE LAKE PHARMA Co.,Ltd. |
|
| CP03 | Change of name, title or address |